Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

naptumomab estafenatox

A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Purpose: To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
2015
2015
Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies. RCC patients in the phase… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2014
Review
2014
Improvement of cancer therapy by introducing new concepts is still urgent even though there have been major advancements lately… Expand
  • figure 1
  • table 1
2013
2013
3073 Background: Naptumomab estafenatox/ANYARA (Nap) is a fusion protein of an antibody (5T4) and a superantigen (SEA/E-120… Expand
2013
2013
The T lymphocytes are the most important effector cells in immunotherapy of cancer. The conceptual objective for developing the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has… Expand
2010
2010
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Review
2010
Review
2010
Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies… Expand
Highly Cited
2009
Highly Cited
2009
PURPOSE Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2006
2006
3083 Background: ABR-217620 (naptumomab estafenatox) is a recombinant fusion protein that consists of the 5T4Fab moiety… Expand